Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prostate Adenocarcinoma With Neuroendocrine Differentiation”

13 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 13 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT02893917
What this trial is testing

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Who this might be right for
Advanced Prostate Adenocarcinoma With Neuroendocrine DifferentiationCastration-Resistant Prostate CarcinomaMetastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation+3 more
National Cancer Institute (NCI) 90
Testing effectiveness (Phase 2)Active Not RecruitingNCT03902951
What this trial is testing

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate AdenocarcinomaProstate Adenocarcinoma With Focal Neuroendocrine DifferentiationRecurrent Prostate Carcinoma+1 more
Jonsson Comprehensive Cancer Center 28
Testing effectiveness (Phase 2)Looking for participantsNCT05691465
What this trial is testing

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Who this might be right for
Metastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationMetastatic Prostate Neuroendocrine CarcinomaMetastatic Prostate Small Cell Neuroendocrine Carcinoma+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT03365791
What this trial is testing

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Who this might be right for
Small Cell Lung CancerGastric AdenocarcinomaEsophageal Adenocarcinoma+5 more
Novartis Pharmaceuticals 76
Very early researchEnded earlyNCT00499733
What this trial is testing

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Who this might be right for
Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Testing effectiveness (Phase 2)Ended earlyNCT03570476
What this trial is testing

Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

Who this might be right for
Prostate Adenocarcinoma Without Neuroendocrine DifferentiationStage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8+3 more
University of Washington 2
Testing effectiveness (Phase 2)Ended earlyNCT03360721
What this trial is testing

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaProstate Adenocarcinoma Without Neuroendocrine DifferentiationStage IV Prostate Cancer AJCC v8+2 more
M.D. Anderson Cancer Center 7
Early research (Phase 1)Active Not RecruitingNCT04514484
What this trial is testing

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Who this might be right for
Advanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular Carcinoma+60 more
National Cancer Institute (NCI) 8
Testing effectiveness (Phase 2)Looking for participantsNCT07179783
What this trial is testing

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Who this might be right for
Prostate Cancer (Adenocarcinoma)Prostate Cancer Metastatic Castration-ResistantProstate Adenocarcinoma With Neuroendocrine Differentiation
Tianjin Medical University Second Hospital 28
Early research (Phase 1)Looking for participantsNCT07080242
What this trial is testing

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Who this might be right for
Small Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine CancerMetastatic or Locally Advanced Neuroendocrine Prostate Cancer+5 more
SystImmune Inc. 120
Early research (Phase 1)Ended earlyNCT05605522
What this trial is testing

[225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Who this might be right for
Pancreatic Ductal Adenocarcinoma (PDAC)Squamous Cell Carcinoma of Head and NeckColorectal Cancer+4 more
3B Pharmaceuticals GmbH 19
Not applicableUnknownNCT03896958
What this trial is testing

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

Who this might be right for
Cancer, All TypesCancer of LiverCancer of Stomach+42 more
SpeciCare 1,000
30